Varenicline is the first new anti-smoking drug in the last ten years ...The new anti-smoking drug varenicline was first licensed for use in ...People become addicted to smoking tobacco partly because nicotine in...This conclusion was drawn by a group of Cochrane researchers after t...Pooling the data showed that people taking varenicline increased the...
Varenicline is the first new anti-smoking drug in the last ten years, and only the third, after NRT and bupropion,// to be licensed in the USA for smoking cessation.
The new anti-smoking drug varenicline was first licensed for use in the UK on 5th December 2006. An early Cochrane Review' of its effectiveness shows that it can give a three-fold increase in the odds of a person quitting smoking.
People become addicted to smoking tobacco partly because nicotine in the smoke stimulates receptors in the nervous system that causes a release of the feel-good hormone dopamine. Varenicline partially stimulates these nicotine receptors and enables a low-level release of dopamine, which reduces withdrawal symptoms. It also partially blocks nicotine from being absorbed by the receptors, making continued smoking less satisfying. This reduces a person’s need to smoke, and may help them to quit completely.
This conclusion was drawn by a group of Cochrane researchers after they studied data from six trials that compared the effects of giving people either varenicline or a placebo. Together the trials involved 2451 people on varenicline and 2473 people on placebos.
Pooling the data showed that people taking varenicline increased their odds of quitting approximately three-fold for 12 months or longer compared with those on placebo drugs.
Data from some of the trials also showed that people given varenicline increased their odds of quitting more than 1?-fold compared with those given bupropion, an antidepressant drug that roughly doubles a person’s chance of stopping smoking.
"What we need now are some trials that make direct comparisons between varenicline and nicotine replacement therapy" says Lead Review Author Kate Cahill, who works in the Department of Primary Health Care at Oxford University.
(Date:11/28/2009)...e/ -- Welcome to syngo® .plaza(1), th... from Siemens Healthcare. As the first Pictu...om Siemens where 2D, 3D, and 4D reading come toget...hange the way multimodality images are read today....h Scientific Assembly and Annual Meeting of the Ra...
(Date:11/27/2009)...ewswire-FirstCall/ -- GSI Group Inc. (Pink Sheets:...chnology products and semiconductor systems, today... shareholders has been scheduled for Friday, April...ill be announced in due course. As previously ann...from Stephen Bershad, a holder of greater than ten...
(Date:11/27/2009)...ewswire-USNewswire/ -- Preventing disease is the g...every year, new vaccines are being added to assist...immunity for the same period of time? And, if not,...p immunity strong? ,, In this month,s issue o...of Pediatrics, Michael Pichichero MD, Director of ...
(Date:11/27/2009)...cal, economic burdens, study predicts , ,...f people with diabetes in the United States is exp...y predicts. , That would bring the total by 203...p from 23.7 million today. , , At the same time,...iple, the study also warns, rising from an estimat...
(Date:11/27/2009)...active anatomy education apps from Modality and Li...nces learning opportunities for iPhone and iPod to...November 27, 2009 -- Modality, Inc. and Lippinco...ters Kluwer Health, today announced the availabili...Store. Clemente’s Anatomy, Rohen’s Pho...
...t to interferon beta treatments , WEDNESDAY, Jan. ...xplain why some multiple sclerosis (MS) patients r...n international study. , Starting with 206 souther... reduced by interferon beta therapy to the DNA of ...
... Center New Orleans has been selected as the inaug...William J. Gies Award for Outstanding Innovation. ...tion at a black-tie celebration on March 29, 2008 .... Gies, a pioneer in dental education, the William...
...ements in key genes connected to the p53 regulator...y creating additional safeguards in human genes to...amage that could cause cancer or a variety of gene...l Academy of Sciences. Because genetically engine...
...hicago are still being exposed to chemicals banned.... The chemicals do not appear to be affecting the ...gs appear in the current issue of the Journal of G...e Illinois Natural History Survey, said that chemi...
... by Reverend Carlton W. Veazey, President and CEO ...:, "On the 35th anniversary of Roe v. Wade, our c...t that abortion will be safe, legal, and available...g promoted in at least 17 states are sounding the ...
...l Costs, WILMINGTON, Del., Jan. 16 Bollig & Kemp...pean auto industry, has signed,a license agreement...logy,that enables auto manufacturers to realize su...acture and sell water-based basecoats for use in t...
(Date:11/25/2009)...25 Reportlinker.com announces that...catalogue: ,, United States Dental Devices Mar...www.reportlinker.com/p0158733/United-States-Dental...l ,, United States Dental Devices Market Analy...is report is an essential source for in-depth info...
(Date:11/25/2009)...v. 25 Abaxis, Inc. (Nasd...ing point-of-care blood analysis systems, announce...ecutive officer, will present at the 21st Annual P...December 2, 2009 at 2:00 p.m. ET. The conference w...rk City. ,, About Abaxis ,, Abaxis develo...
(Date:11/25/2009)... Nov. 25 According to Millennium R...al technology market intelligence, the nearly $3 b...continue to see rapid growth over the next five ye...S Markets for Trauma Devices 2010 report finds ...he next five years, with competitors introducing s...
...ce for unique Ranexa(R) mechanism of action -, CH...VTX ) announced today that ranolazine significantl...nts with a hereditary form of long QT,syndrome cal... the late,sodium channel and can be associated wit...anolazine also shortened cardiac relaxation time i...
...y re-evaluates this important question with today,...GO, March 30 Percutaneous coronary intervention,(...ed balloons and stents,to open a completely blocke...art -- is the best treatment for heart attack when...t the 90-minute treatment goal unless they,have a ...